Compare SanDisk (SNDK) vs TG Therapeutics Inc (TGTX) Price & Performance

SNDK trades at $1,581.82, down 6.54% amid recent volatility, yet maintains strong analyst support with 87.5% buy ratings and a $2,160 consensus price target. The stock shows exceptional profitability metrics including 71.47% gross margins and 91.64% ROE, though current earnings reflect a net loss of -$1.64B for 2025. Recent news highlights institutional positioning shifts and AI-driven memory demand dynamics affecting performance.

Outlook remains cautiously optimistic given projected 2026 revenue growth to $20.2B and net profit of $11.4B, but risks include memory cycle volatility and competitive pressures. Technical indicators suggest near-term bearish pressure with key support at $1,575, while fundamental strength in profitability metrics supports long-term growth potential.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.